Pain News and Research

Latest Pain News and Research

Poster presentation at MASCC Conference summarizes MuGard clinical experience

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy.

28 Jun 2010

Kansas doctor and wife found guilty of prescribing painkillers, causing deaths

"A federal jury Thursday found a Kansas doctor and his wife guilty of conspiring to profit from illegally prescribing painkillers to dozens of patients who later died, in a case highlighting medical treatment of chronic pain sufferers and prescription drug abuse."

28 Jun 2010

PecFent receives Positive Opinion from CHMP for treatment of BTCP

Archimedes Pharma, a leading specialty pharma company, today announced that its lead product, PecFent, has received a Positive Opinion from the Committee for Human Medicinal Products, of the European Medicines Agency. The CHMP is recommending PecFent, an innovative fentanyl nasal spray, be authorised for marketing in European Union countries for the treatment of breakthrough cancer pain - sudden, unpredictable episodes of intense pain that occur despite background pain medication.

25 Jun 2010

Researchers uncover association between free radical-mediated reactions and progression of SLE

University of Texas Medical Branch researchers have uncovered an association between free radical-mediated reactions and the severity and progression of system lupus erythematosus. Higher levels of oxidative and nitrosative stress markers were found in SLE patients with greater disease activity suggesting a causal relationship. Full findings of the study are available in the July issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

25 Jun 2010

Scientists report first preliminary description of bed bug's sialome

With bed bugs reemerging as a nuisance in some parts of the country, scientists are reporting the first preliminary description of the bug's sialome - the saliva proteins that are the secret to Cimex lectularius' ability to suck blood from its human victims and escape to bite again with risking a lethal slap. The findings, which could have medical applications in diagnosing bed bug bites and preventing the itch, appear in ACS' monthly Journal of Proteome Research.

25 Jun 2010

Specific virus can interact with mutation in host's genes to trigger diseases: Scientists

Scientists have shown that a specific virus can interact with a mutation in the host's genes to trigger disease. The observation may help explain why many people with disease risk genes do not actually develop disease.

25 Jun 2010

Two experimental drugs have potential to restore pumping strength to failing hearts, study finds

We've all experienced the strong heartbeat that accompanies emotions such as fear and rage. But can the body's natural response to these emotions be used to combat heart failure? Results of a study published online today in the journal Circulation Research present a strong case.

25 Jun 2010

Japanese researchers identity useful markers for early diagnosis of CMV gastritis

Cytomegalovirus (CMV) disease is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-SCT), which is widely accepted as a curative therapy for advanced hematological malignancies including leukemia and malignant lymphoma.

25 Jun 2010

CDP treatment can reduce pain and swelling in CVI patients

For patients with painful swelling of the legs caused by chronic venous insufficiency (CVI), a combination treatment approach called "complete decongestive physiotherapy" improves symptoms, walking ability, and quality of life, reports a study in Topics in Geriatric Rehabilitation.

25 Jun 2010

$Repetitive impact on feet can increase risk of stress fractures$

Repetitive impact on feet can increase risk of stress fractures

Stress fractures of the foot are becoming more common in runners, especially first-time marathoners, according to the American College of Foot and Ankle Surgeons.

25 Jun 2010

Cardio-respiratory aerobic exercise reduces joint pain in RA patients

Researchers from the University of Grenoble Medical School in France determined that cardio-respiratory aerobic exercise is safe for patients with stable rheumatoid arthritis (RA).

25 Jun 2010

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs.

24 Jun 2010

FDA grants t2cure orphan drug designation for t2c001 in Buerger's Disease

t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the FDA has granted orphan drug designation to t2c001 for the treatment of Buerger's Disease. The Company also announced that in a concurrent application in Europe the EMA's Committee for Orphan Medicinal Products recently recommended t2c001 for orphan designation to the European Commission.

24 Jun 2010

Researchers find why patients with XPV are more susceptible to skin cancer

Researchers from Mount Sinai School of Medicine have found why patients with a variant form of xeroderma pigmentosum, an inherited genetic disorder characterized by extreme sensitivity to the sun, are more susceptible to skin cancers than the general population. The data are published in the current issue of the journal Nature. Their finding sets the stage for research into therapies that would help protect people with XPV from developing skin cancers.

24 Jun 2010

June issue of Clinic Women's HealthSource provides overview of anemia

Anemia is not a normal part of aging, yet it's fairly common in older adults and causes frailness, weakness and increased risk of falls. According to Mayo Clinic Women's HealthSource, more than one in 10 older adults has anemia. Twenty percent of women are anemic by age 85.

24 Jun 2010

Ways to manage hammertoe pain

The pain from hammertoe, a deformity that can cause one or more toes to assume a claw shape, can curtail an evening of dancing or make a favorite pair of shoes unwearable. But, according to the June issue of Mayo Clinic Health Letter, this condition often can be managed by proper footwear or simple toe coverings.

24 Jun 2010

Pfizer announces suspension of osteoarthritis clinical program for tanezumab

Pfizer Inc. announced today the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration. The worldwide suspension – which is effective immediately – follows a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement.

24 Jun 2010

Treatment options for patients with MS

The best one-word description for multiple sclerosis is "unpredictable," according to the June issue of Mayo Clinic Women's HealthSource. MS interferes with the communication between the brain and the rest of the body. Just how that interference plays out in symptoms is different for everyone -- thus, the unpredictable label.

24 Jun 2010

Watson's ANDA for Fentanyl Citrate Buccal tablets receives tentative FDA approval

Watson Pharmaceuticals, Inc. announced that its subsidiary, Watson Laboratories, Inc. has received tentative approval today from the United States (U.S.) Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Fentanyl Citrate Buccal tablets, 100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg and 800 mcg.

24 Jun 2010

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, June 25 from 3:30 to 4:00 pm PT. The presentation will show that the Company's investigational LEVADEX™ orally inhaled migraine therapy was effective irrespective of when it was administered during a migraine cycle.

23 Jun 2010

Pain News and Research

Latest Pain News and Research

Poster presentation at MASCC Conference summarizes MuGard clinical experience

Kansas doctor and wife found guilty of prescribing painkillers, causing deaths

PecFent receives Positive Opinion from CHMP for treatment of BTCP

Researchers uncover association between free radical-mediated reactions and progression of SLE

Scientists report first preliminary description of bed bug's sialome

Specific virus can interact with mutation in host's genes to trigger diseases: Scientists

Two experimental drugs have potential to restore pumping strength to failing hearts, study finds

Japanese researchers identity useful markers for early diagnosis of CMV gastritis

CDP treatment can reduce pain and swelling in CVI patients

Repetitive impact on feet can increase risk of stress fractures

Cardio-respiratory aerobic exercise reduces joint pain in RA patients

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

FDA grants t2cure orphan drug designation for t2c001 in Buerger's Disease

Researchers find why patients with XPV are more susceptible to skin cancer

June issue of Clinic Women's HealthSource provides overview of anemia

Ways to manage hammertoe pain

Pfizer announces suspension of osteoarthritis clinical program for tanezumab

Treatment options for patients with MS

Watson's ANDA for Fentanyl Citrate Buccal tablets receives tentative FDA approval

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Pain News and Research

Latest Pain News and Research

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in